Achieve Life Sciences (STU:SP4P) Scaled Net Operating Assets: -0.09 (As of Mar. 2026)


STU:SP4P Achieve Life Sciences Inc STU:SP4P
32 GF Score
Price €5.35
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences Scaled Net Operating Assets?

Achieve Life Sciences STU:SP4P -3.60% 32 Scaled Net Operating Assets is -0.09 as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Achieve Life Sciences's operating assets for the quarter that ended in Mar. 2026 was €3.32 Mil. Achieve Life Sciences's operating liabilities for the quarter that ended in Mar. 2026 was €6.47 Mil. Achieve Life Sciences's Total Assets for the quarter that ended in Dec. 2025 was €35.69 Mil. Therefore, Achieve Life Sciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was -0.09.

Achieve Life Sciences Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences Scaled Net Operating Assets Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.01 -0.01 -0.19 0.00

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.13 -0.08 0.00 -0.09

STU:SP4P vs STTK, CRMD, EIKN: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Achieve Life Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Achieve Life Sciences Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Scaled Net Operating Assets falls into.


STU:SP4P
32GF Score
Achieve Life Sciences Inc STU:SP4P
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Achieve Life Sciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(4.617-4.541)/36.895
=0.00

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=35.689 - 31.072
=4.617

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=17.312 - 9.556 - 3.215
=4.541

Achieve Life Sciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(3.318-6.465)/35.689
=-0.09

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=28.636 - 25.318
=3.318

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=19.399 - 8.064 - 4.87
=6.465

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.09 mean?
Achieve Life Sciences (STU:SP4P) has a Scaled Net Operating Assets of -0.09 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Achieve Life Sciences and its competitors.
Is Achieve Life Sciences' Scaled Net Operating Assets too high?
Achieve Life Sciences' current Scaled Net Operating Assets is -0.09. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' Scaled Net Operating Assets compare to STTK and CRMD?
Achieve Life Sciences' Scaled Net Operating Assets of -0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current Scaled Net Operating Assets is -0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current Scaled Net Operating Assets of -0.09. The current Scaled Net Operating Assets is -0.09. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current Scaled Net Operating Assets is -0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score

Get the complete analysis for STU:SP4P

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.35
Price